



HAL
open science

Transcriptome Analysis during Human Trophectoderm Specification Suggests New Roles of Metabolic and Epigenetic Genes.

Said Assou, Imène Boumela, Delphine Haouzi, Cécile Monzo, Hervé Dechaud, Issac-Jacques Kadoch, Samir Hamamah

► **To cite this version:**

Said Assou, Imène Boumela, Delphine Haouzi, Cécile Monzo, Hervé Dechaud, et al.. Transcriptome Analysis during Human Trophectoderm Specification Suggests New Roles of Metabolic and Epigenetic Genes.. PLoS ONE, 2012, 7 (6), pp.e39306. 10.1371/journal.pone.0039306 . inserm-00726672

HAL Id: inserm-00726672

<https://inserm.hal.science/inserm-00726672>

Submitted on 31 Aug 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Transcriptome Analysis during Human Trophectoderm Specification Suggests New Roles of Metabolic and Epigenetic Genes

Said Assou^{1,2,3}, Imène Boumela^{1,2,3}, Delphine Haouzi¹, Cécile Monzo^{1,2}, Hervé Dechaud^{1,2,3}, Issac-Jacques Kadoch⁴, Samir Hamamah^{1,2,3*}

1 CHU Montpellier, Institute for Research in Biotherapy, Hôpital Saint-Eloi, INSERM U1040, Montpellier, France, **2** Université MONTPELLIER1, UFR de Médecine, Montpellier, France, **3** ART-PGD department, CHU Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France, **4** Département d'Obstétrique Gynécologie, Université de Montréal, Hôpital Saint-Luc du CHUM, Montréal, Canada

Abstract

In humans, successful pregnancy depends on a cascade of dynamic events during early embryonic development. Unfortunately, molecular data on these critical events is scarce. To improve our understanding of the molecular mechanisms that govern the specification/development of the trophoblast cell lineage, the transcriptome of human trophectoderm (TE) cells from day 5 blastocysts was compared to that of single day 3 embryos from our *in vitro* fertilization program by using Human Genome U133 Plus 2.0 microarrays. Some of the microarray data were validated by quantitative RT-PCR. The TE molecular signature included 2,196 transcripts, among which were genes already known to be TE-specific (*GATA2*, *GATA3* and *GCM1*) but also genes involved in trophoblast invasion (*MUC15*), chromatin remodeling (specifically the DNA methyltransferase *DNMT3L*) and steroid metabolism (*HSD3B1*, *HSD17B1* and *FDX1*). In day 3 human embryos 1,714 transcripts were specifically up-regulated. Besides stemness genes such as *NANOG* and *DPPA2*, this signature included genes belonging to the *NLR* family (*NALP4*, 5, 9, 11 and 13), Ret finger protein-like family (*RFPL1*, 2 and 3), Melanoma Antigen family (*MAGEA1*, 2, 3, 5, 6 and 12) and previously unreported transcripts, such as *MBD3L2* and *ZSCAN4*. This study provides a comprehensive outlook of the genes that are expressed during the initial embryo-trophectoderm transition in humans. Further understanding of the biological functions of the key genes involved in steroidogenesis and epigenetic regulation of transcription that are up-regulated in TE cells may clarify their contribution to TE specification and might also provide new biomarkers for the selection of viable and competent blastocysts.

Citation: Assou S, Boumela I, Haouzi D, Monzo C, Dechaud H, et al. (2012) Transcriptome Analysis during Human Trophectoderm Specification Suggests New Roles of Metabolic and Epigenetic Genes. PLoS ONE 7(6): e39306. doi:10.1371/journal.pone.0039306

Editor: Francisco José Esteban, University of Jaén, Spain

Received: December 8, 2011; **Accepted:** May 18, 2012; **Published:** June 22, 2012

Copyright: © 2012 Assou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Ferring and Genevrier pharmaceutical companies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Competing Interests: The authors have read the journal's policy and have the following conflicts: This study was funded by Ferring and Genevrier pharmaceutical companies. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: s-hamamah@chu-montpellier.fr

¶ These authors contributed equally to this work.

Introduction

Pre-implantation development of mammalian embryos encompasses a series of critical dynamic events, such as the transition from a single-cell zygote to a multicellular blastocyst and the first segregation of cells within the embryo with the formation of the inner cell mass (ICM) surrounded by trophectoderm (TE) cells. ICM retains pluripotency and gives rise to the embryo proper, whereas TE cells play an important role in embryonic implantation in the uterine endometrium and placental formation. In humans, the embryonic genome activation (EGA) program is functional by day 3 after fertilization [1]. The 6–8 cell stage embryo (day 3 post-fertilization) starts the process of “compaction” that leads to the generation of the tightly organized cell mass of the morula and is followed by differentiation of the morula into a blastocyst [2]. The transition from day 3 embryos to day 5 blastocysts is likely to be controlled by many and specific changes in the expression of different genes as this process involves both

cellular differentiation and transcriptional reprogramming. Although some genes that are specifically expressed in day 3 human embryos and in TE cells, such as *CCNA1* and *GATA3* respectively have been identified [3,4], our knowledge on the changes in gene expression associated with the initial embryo-TE transition and the specification of the TE cell lineage is still limited. In addition, since TE biopsies from day 5 human blastocysts might become a reliable alternative to blastomere biopsies to assess the expression of biomarkers of embryo viability [5], a better knowledge of the genes that are specifically expressed in TE cells and the embryo proper is crucial. Recent technological advances in mRNA amplification methods and DNA microarray assays have allowed the simultaneous analysis of the transcript level of thousands of genes in one experiment, thus offering a global view of the molecular events regulating physiological functions and cellular processes [6,7]. Indeed, these methodologies have already contributed to improving our knowledge on the genetic network controlling key stages of pre-implantation embryo development

[8,9,10,11]. In this study, we used high-density oligonucleotide Affymetrix HG-U133P microarray chips to analyze the gene transcription profiles of single day 3 human embryos and TE cells isolated from day 5 blastocysts. By comparing the transcriptomes of TE cells and day 3 embryos, we identified the specific molecular signature of human TE cells. These findings should provide a base for investigating the molecular mechanisms of the embryo-TE transition as well as important insights for the development of diagnostic tests to test blastocyst quality in assisted reproduction programs.

Results

Dynamic Changes in Overall Gene Expression in Mature MII Oocytes, Single Day 3 Embryos, TE Cells from Day 5 Blastocysts and hESCs

In order to determine the global gene expression variation in the different samples, we established the gene expression profile of mature MII oocytes (n=3), day 3 single embryos (n=6), TE samples from day 5 blastocysts (n=5) and hESCs (n=4) (to represent the ICM) by using high-density oligonucleotide Affymetrix HG-U133P microarray chips. A non-supervised analysis using the principal components analysis (PCA) showed that samples from the same group clustered together very tightly (Figure 1A), corroborating the robustness of the Affymetrix microarrays [12]. Moreover, a non-supervised hierarchical clustering analysis of the array data (based on 15,000 genes) clustered perfectly the different samples, confirming their very specific expression profiles (Figure 1B). Finally, a scatter plot analysis (Figure S1) showed that expression variations between mature MII oocytes and single day 3 embryos were high as illustrated by the dispersed scatter plots and the low correlation coefficient (0.51). Conversely, the differences in gene expression between day 3 embryos and TE or hESC samples were lower as indicated by the tighter scatter plots and the high correlation coefficients (0.60–0.76) (Figure S1). These results reveal dynamic transcriptome changes during the transition from mature oocyte to day 3 embryo and from day 3 embryo to blastocyst. These “dynamic patterns” are due to the large-scale degradation of human maternal transcripts and the activation of embryonic genes, as was also observed in the mouse [10,13].

Comparison of the Gene Expression Profiles of Day 3 Embryos and TE Cells Isolated from Day 5 Blastocysts

We then compared the expression profiles of day 3 embryos and TE cells, by using the significance analysis of microarrays (SAM) software with a 2-fold change cut-off and false discovery rate (FDR) <1%. We found that 2,196 transcripts were up-regulated in human TE cells (“TE molecular signature”) and 1,714 in day 3 embryos (“day 3 embryo molecular signature”) (Figure 2). The comprehensive lists of these signatures are presented in Tables S1 and S2 and the 100 genes with the highest fold change and significant statistical value (FDR = 0) for each signature are listed in Table 1 and 2. The “day 3 embryo molecular signature” included the Developmental Pluripotency Associated gene 5 (*DPPA5*), members of the Ret finger protein-like gene family (*RFPL1*, 2 and 3), of the NLR family (*NALP4*, 5, 9, 11 and 13), and of the melanoma antigen family (*MAGEA1*, 2, 3, 5, 6 and 12). Several maternal genes were found in this signature, such as members of the Zona Pellucida gene family (*ZP2*, 3 and 4), *ZAR1*, *AURKC* and *FIGLA*, suggesting that they are still active in day 3 embryos. Several transcription factors were also significantly over-expressed in day 3 embryos, such as *TFBIM* and *TFB2M*, the transcriptional regulators *MBD3L2* and *ZSCAN4*, as well as metabolic genes such as Pyruvate Dehydrogenase Kinase 3

(*PDK3*) and Lactate Dehydrogenases (*LDHC*). The “TE molecular signature” comprised genes important for placental development (*PGF* and *TFAP2A*), cytoskeleton-associated genes (*Keratin 18* and *19*), and genes encoding S100 calcium binding proteins (*S100P*, *S100A6*, 10, 13, 14 and 16), retinoid receptor-related testis-associated receptors (*NR2F2* and *NR2F6*) or the B receptor (*CCKBR*). Moreover, genes encoding extracellular matrix proteins, such as Laminins (*LAMA1*, *LAMA5* and *LAMC1*) and Integrins (*ITGB4* and *ITGB5*) were also up-regulated. Gene ontology (GO) annotations were used to explore the specific functional properties of the two molecular signatures (Figure 3). The day 3 embryo molecular signature was enriched in genes associated with localization in the “nucleus”, while genes associated with the “cytoplasm” localization were over-represented in the TE molecular signature. Concerning the “biological processes”, the day 3 embryo molecular signature was enriched in genes involved in the regulation of cellular processes, transcription and post-translational protein modifications. Conversely, in the TE molecular signature, genes connected with different metabolic and steroid biosynthetic processes were over-represented. The “molecular function” analysis showed that genes involved in oxidoreductase activity were significantly enriched in the TE signature ($p < 0.001$), whereas genes related to “GTPase activity” and DNA binding were over-represented in the day 3 embryo signature. Finally, the expression pattern of 11 genes belonging to the TE (*GATA3*, *LAMA1*, *KRT18*, *HSD3B1*, *HSD17B1* and *DNMT3L*) or to the day 3 embryo molecular signature (*MBD3L2*, *CCNA1*, *BIK*, *RFPL2* and *FIGLA*) was confirmed by qRT-PCR analysis using specific primer pairs (Table S3). All qRT-PCR data were normalized to *GAPDH* to control for variations in mRNA recovery and RT efficiency (Figure S2).

Expression of Genes Encoding Proteins which Play a Role in Apoptosis in Day 3 Embryos and TE Samples

We then investigated the expression of genes coding for proteins linked to the extrinsic and intrinsic apoptosis pathways in day 3 embryos and TE cells. The expression of genes of the *TNF* ligand and receptor family was not different in day 3 embryos and TE cells. Conversely, several genes belonging to the *BCL-2*, *BIRC* and *Caspase* families appeared to be differentially expressed in the two groups (Figure 4A). Specifically, the *BCL-2* family members *BCL2L10* ($\times 37$, FDR <0.0001), *BCL2L11* ($\times 16$, FDR <0.001), and *BIK* ($\times 3.7$, FDR <0.001), the expression of which was validated by qRT-PCR (Figure 3), and the *BIRC* family member *BIRC2* ($\times 4$, FDR <0.001) were up-regulated in day 3 embryos. *Caspase 6* ($\times 3$, FDR <0.001) was over-expressed in TE cells. *MCL-1*, a gene that belongs to the *BCL2* family and promotes cell survival, was strongly expressed in both day 3 embryos and TE samples.

Evaluation of DNA Repair Regulation in Day 3 Embryos and TE Samples

The microarrays data were also used to investigate the expression of a comprehensive list of DNA repair genes [14] in day 3 embryos and TE samples (Tables S1 and S2). Of the 123 DNA damage repair genes investigated, five [*UNG*, *RFCL1*, *UNG2* (now named *CCNO*), *PCNA*, *MSH2*] were up-regulated in day 3 embryos and eleven [*BRCA1*, *TDG*, *FANCG*, *FEN1*, *XRCC5*, *XRCC6*, *XPC*, *MUTYH*, *XPA*, *SMUG1*, *POLD2*] in TE cells. We then analyzed the functional relationship between the DNA damage repair genes that were differentially expressed in TE samples and day 3 embryos using the Ingenuity Pathway Analysis (IPA) software. In both cases, all the DNA repair genes displayed a




Figure 1. Gene expression patterns of day 3 human embryos, mature MII oocytes, TE cells and hESC cells. (A) PCA two-dimensional scatter plots represent the differential gene expression patterns of the different human samples. Each dot represents a sample and the color its origin: oocytes (green dots), day 3 embryos (blue dots), TE from day 5 embryos (black dots) and hESCs (red dots). Samples can be divided in four distinct areas based on their gene expression. (B) Average-link hierarchical clustering of 15,000 genes delineated four major gene clusters: (a) genes specifically detected in mature MII oocytes; (b) genes over-expressed in hESCs; (c) genes up-regulated in TE and (d) genes specifically over-expressed in day 3 embryos.

doi:10.1371/journal.pone.0039306.g001

documented functional interaction with each other, forming a tightly connected network (Figure S3).

Stemness Genes and Transcriptional Regulatory Networks Identified in Day 3 Embryos and TE Cells

We then performed a stemness gene enrichment analysis using a previously published dataset from hESCs, in which we defined a consensus hESC stemness gene list ($n = 48$ genes) [7]. The key stemness factors *NANOG*, *POU5F1* (*OCT3/4*) and *SOX2* [15] were enriched in day 3 human embryos, whereas *DNMT3B*, *LN28*, *PHF17*, *SEPHS1* were over-represented in TE cells. Conversely, other genes, such as *UGP2* and *PIM2*, were enriched in both day 3 embryos and TE samples (Figure 4B). Bioinformatic gene pathway analysis (Ingenuity software) of the day 3 embryo molecular signature showed that many genes of the *NANOG* signaling pathway, including *NANOG* (Figure 5), were up-regulated in day 3 human embryos, thus confirming the role of *NANOG* in the maintenance of pluripotency [16]. The “TE molecular signature” included transcription factors such as *GCM1*, which is induced by Transforming Growth Factor- β (*TGF- β*) [17], and Bone Morphogenic Protein 4 (*BMP4*) that induces the differentiation of pluripotent stem cells to trophoblast cells [18,19]. Other components of the *TGF- β* signaling cascade, such as Transforming Growth Factor Beta Receptor III (*TGFBR3*), were also included in the “TE molecular signature”.

Dynamic Expression of Epigenetic and Metabolic Regulators During Trophoblast Development

Since specification of the TE lineage during blastocyst formation involves initiation of differentiation, it is likely that epigenetic regulators may have an important role in this first developmental decision. The majority of the epigenetic regulators that were up-regulated in TE cells are associated with a repressive epigenetic status (Figure 5). Specifically, the expression of the DNA methyltransferases (DNMT) *DNMT3A*, *DNMT3B* and *DNMT1* increased between 2- and 13-fold in TE cells in comparison to day 3 embryos. *DNMT3L* expression was 70-fold higher in TE samples than in day 3 embryos. Similarly, several transcripts coding for proteins involved in chromatin remodeling and histone modification (*SMARCA4*, *SMARCC1* and *SMARCE1*) were up-regulated between 2- and 7-fold in TE cells. Conversely, many histone deacetylases (*HDAC9* and *HDAC2*) and histone acetyltransferases (*HAT1*, *SETD8*, *RNF20*, *TAF1*, *STK17B*, *31*, *32B* and *35*) were down-regulated in TE cells in comparison to day 3 embryos. Another feature of the TE molecular signature was the up-regulation of several metabolic genes. Specifically, genes that are involved in estrogen biosynthesis (*CYP11A1* $\times 35$, *CYP19A1* $\times 14$) and lipid metabolism (*PTGES* $\times 20$) were strongly up-regulated in TE cells. One of the most striking observations was the high expression of genes that are involved in steroidogenesis (*HSD3B1* $\times 383$, *STS* $\times 135$, *HSD17B1* $\times 108$, *FDX1* $\times 14$ and *SRA1* $\times 6$).




Figure 2. Day 3 embryo and TE molecular signatures: Heat map of the molecular signatures in six day 3 embryos and five TE samples. Each horizontal line represents a gene and each column represents a single sample. The color intensity indicates the level of gene expression (red for up-regulation and blue for down-regulation) “see also Table S1 and S2”. doi:10.1371/journal.pone.0039306.g002

Intersection with the Transcriptomes of Mature MII Oocytes and hESCs

In an effort to link the genes involved in the day 3 embryo-TE transition with early embryonic development, we further investigated differences and similarities in the gene expression patterns of MII oocytes, day 3 embryos, TE cells and hESCs samples (comprehensive list in Table S4). The genes that were found to be up-regulated in day 3 embryos (Table S1) and TE cells (Table S2) were individually compared to those up-regulated in MII oocytes and hESCs using Venn diagrams (Figure S4). Only 36 genes were common to both the TE and the MII oocyte signatures. On the other hand, day 3 embryos and MII oocytes shared a set of 511 genes, among which many are associated with oogenesis, such as *DAZL*, *GDF9* and *FIGLA*. Finally, 1263 genes were common to both TE and hESC profiles, whereas only 124 genes were shared by day 3 embryos and the hESCs. Genes that were up-regulated in both TE and hESC samples were associated with cell death and proliferation (*BAG6*, *CASP2* and *ANXA3*), metabolism (*GCDH* and *HPGD*) and WNT signaling (*FZD5*, *AXIN1* and *TCF3*). Genes that were up-regulated in both day 3 embryos and hESCs (124 genes) are involved in the maintenance of pluripotency and tissue development, such as *NANOG*. Among the genes specifically up-regulated in TE samples (644 genes), key genes related to epigenetic and metabolic pathways, such as *DNMT3L*, *HSD3B1* and *HSD17B1*, were observed.

Discussion

Here, we compared the transcriptomes of day 3 human embryos and TE cells from day 5 human blastocysts to identify transcripts that are differentially expressed during the embryo-to-TE transition and the specification of the TE cell lineage. Many of the genes that were up-regulated in TE cells are already known to be associated with human TE differentiation [20,21]. For instance, we confirmed that *GATA3* and *KRT18*, two trophoblast-determining genes, are enriched in TE from human blastocysts [22]. Moreover, the “TE molecular signature” included also unexpected genes, the TE-specificity of which has been overlooked. For instance, *CCKBR* activates signaling pathways involved in cell proliferation or migration [23,24] and stimulates the expression of $\beta 1$ -Integrin *in vitro* [25]. A number of cell adhesion genes that might be implicated in the embryo attachment to the endometrium were also up-regulated in TE cells, including members of the Integrin family (*ITGB5*) and genes related to extracellular matrix remodeling, such as Laminins (*LAMA1* and *LAMC1*). In humans, active steroid hormones, including progesterone that is secreted by mouse TE cells [26], are essential for implantation and maintenance of pregnancy. Our analysis reveals that *HSD3B1*, *HSD17B1* and *FDX1*, which encode enzymes involved in the metabolism of cholesterol, were specifically up-regulated in TE cells in comparison to day 3 embryos (Figure S5). Moreover, *PTGES* (Prostaglandin E synthase) as well as *CYP11A1* and *CYP19A1* (estrogen synthesis) were also up-regulated in TE cells, suggesting a central role of these steroidogenic enzymes in TE steroid biosynthesis and




Figure 3. Gene Ontology (GO) annotations of the day 3 embryo and TE molecular signatures. We compared the GO annotations of genes specifically over-expressed in day 3 embryos and in TE cells by using the Babelomics web tool (<http://babelomics.bioinfo.cipf.es/>). Histograms show the percentage of genes with a specific GO annotation in day 3 embryos (white) or in TE samples (black). Only GO categories which differed significantly (p value <0.01) between the two groups are shown. doi:10.1371/journal.pone.0039306.g003

metabolism. Thus, the TE joins the group of tissues with “steroidogenic” activity, such as brain, heart, gonads, endometrium and placenta [27,28]. It is now important to compare the steroidogenic gene expression profiles in TE cells isolated from good and bad quality blastocysts to fully correlate specific transcriptional events with efficient TE development.

Among the models used to study trophoblast development, hESCs have emerged as a useful tool to examine the emergence and differentiation of TE cells. Particularly, the transcriptomic analysis of TE cells derived from hESCs has provided new insights into the signaling pathways and the molecular mechanisms underlying early trophoblast development. Recently, by using a microarray approach, Marchand and colleagues investigated gene expression during differentiation of hESCs into the trophoblast lineage upon addition of Bone Morphogenetic Protein 4 (BMP4) for 10 days and identified 670 genes that were up-regulated from day 0 to day 10 [29]. By intersecting these genes with those we found to be up-regulated in TE cells isolated from day 5 embryos, we found 104 common genes (see Table S5) among which there were not only trophoblast markers (for instance, *GATA3* and

KRT19), but also many genes implicated in lipid metabolism and estrogen biosynthesis (i.e., *CYP19A1*, *CYP11A1*, *HSD17B1*, *HSD3B1*, *PTGES*, *STS*, *HPGD*, *SLCO2A1*, *HMOX1*, *ABCG2*, *ASAHI* and *SMPD1*). This finding validates the importance of metabolic genes during TE specification. Aghajanova et al. [30] compared the transcriptome of embryo-derived TE cells with that of hESC-derived TE cells and found that most of the shared genes were involved in the development of receptive endometrium during implantation. Suzuki et al. [31] used human embryonic carcinoma cells (G3), which can differentiate into TE cells, as an experimental model to investigate the molecular mechanism of trophoctoderm differentiation. Thus, comparative studies using human TE and hESC or G3 cells are relevant to better understand the molecular basis of cell fate decisions and to develop models of human TE development.

The “day 3 embryo molecular signature” was enriched in genes from the *NLRP* (named *NALP*) family which might play a role in early embryo development [32,33]. Indeed, *NLRP5*, *NLRP8* and *NLRP9* are expressed in bovine and human pre-implantation embryos [32,34] and, in pregnant *NLRP5* null female mice,

Table 1. List of the 100 genes with the highest fold change in day 3 human embryos in comparison to TE samples.

| Probesets | Gene Name | Gene Title | UniGene | Chromosomal Location | Fold change | FDR (%) |
|--------------|-----------|--|-----------|----------------------|-------------|---------|
| 1552531_a_at | NALP11 | NLR family, pyrin domain containing 11 | Hs.375039 | chr19q13.42 | 1893 | 0 |
| 242334_at | NALP4 | NLR family, pyrin domain containing 4 | Hs.631533 | chr19q13.42 | 892 | 0 |
| 214957_at | ACTL8 | actin-like 8 | Hs.2149 | chr1p36.2-p35 | 755 | 0 |
| 1556096_s_at | UNC13C | unc-13 homolog C | Hs.443456 | chr15q21.3 | 663 | 0 |
| 207443_at | NR2E1 | nuclear receptor subfamily 2, group E, member 1 | Hs.157688 | chr6q21 | 625 | 0 |
| 1553619_a_at | TRIM43 | tripartite motif-containing 43 | Hs.589730 | chr2q11.1 | 519 | 0 |
| 1552405_at | NALP5 | NLR family, pyrin domain containing 5 | Hs.356872 | chr19q13.42 | 448 | 0 |
| 209160_at | AKR1C3 | aldo-keto reductase family 1, member C3 | Hs.78183 | chr10p15-p14 | 431 | 0 |
| 1552456_a_at | MBD3L2 | methyl-CpG binding domain protein 3-like 2 | Hs.567667 | chr19p13.2 | 394 | 0 |
| 1557085_at | TMEM122 | placenta-specific 1-like | Hs.132310 | chr11q12.1 | 387 | 0 |
| 39318_at | TCL1A | T-cell leukemia/lymphoma 1A | Hs.2484 | chr14q32.1 | 342 | 0 |
| 234393_at | HDAC9 | histone deacetylase 9 | Hs.196054 | chr7p21.1 | 315 | 0 |
| 1552912_a_at | IL23R | interleukin 23 receptor | Hs.200929 | chr1p31.3 | 306 | 0 |
| 1552852_a_at | ZSCAN4 | zinc finger and SCAN domain containing 4 | Hs.469663 | chr19q13.43 | 282 | 0 |
| 226117_at | TIFA | TRAF-interacting protein with a forkhead-associated domain | Hs.310640 | chr4q25 | 275 | 0 |
| 222361_at | LOC643224 | similar to tubulin, beta 8 | Hs.551805 | chr9q34.3 | 273 | 0 |
| 229105_at | GPR39 | G protein-coupled receptor 39 | Hs.432395 | chr2q21-q22 | 255 | 0 |
| 225626_at | PAG1 | phosphoprotein associated with glycosphingolipid microdomains 1 | Hs.266175 | chr8q21.13 | 230 | 0 |
| 1557544_at | C10orf80 | chromosome 10 open reading frame 80 | Hs.253576 | chr10q25.1 | 209 | 0 |
| 210634_at | KLHL20 | kelch-like 20 (Drosophila) | Hs.495035 | chr1q24.1-q24.3 | 206 | 0 |
| 206343_s_at | NRG1 | neuregulin 1 | Hs.453951 | chr8p21-p12 | 184 | 0 |
| 207213_s_at | USP2 | ubiquitin specific peptidase 2 | Hs.524085 | chr11q23.3 | 182 | 0 |
| 1563120_at | Hs.623820 | Homo sapiens, clone IMAGE:5528155, mRNA | Hs.630724 | | 175 | 0 |
| 237131_at | LOC645469 | hypothetical protein FLJ36032 | Hs.297967 | chr1q21.3 | 172 | 0 |
| 221630_s_at | DDX4 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 | Hs.223581 | chr5p15.2-p13.1 | 171 | 0 |
| 241550_at | DPPA5 | developmental pluripotency associated 5 | Hs.125331 | chr6q13 | 167 | 0 |
| 217365_at | PRAMEF5 | similar to PRAME family member 6 | | chr1p36.21 | 157 | 0 |
| 1570337_at | FIGLA | folliculogenesis specific basic helix-loop-helix | Hs.407636 | chr2p13.3 | 157 | 0 |
| 206140_at | LHX2 | LIM homeobox 2 | Hs.445265 | chr9q33-q34.1 | 154 | 0 |
| 229738_at | DNAH10 | dynein, axonemal, heavy chain 10 | Hs.622654 | chr12q24.31 | 154 | 0 |
| 209785_s_at | PLA2G4C | phospholipase A2, group IVC (cytosolic, calcium-independent) | Hs.631562 | chr19q13.3 | 149 | 0 |
| 237613_at | FOXR1 | forkhead box R1 | Hs.116679 | chr11q23.3 | 147 | 0 |
| 236914_at | AW080028 | | | | 137 | 0 |
| 210467_x_at | MAGEA12 | melanoma antigen family A, 12 | | chrXq28 | 137 | 0 |
| 242128_at | OTX2 | orthodenticle homolog 2 (Drosophila) | Hs.288655 | chr14q21-q22 | 128 | 0 |
| 220535_at | FAM90A1 | family with sequence similarity 90, member A1 | Hs.196086 | chr12p13.31 | 128 | 0 |
| 215048_at | SUHW2 | suppressor of hairy wing homolog 2 (Drosophila) | Hs.43834 | chr22q11.22 | 127 | 0 |
| 207934_at | RFPL1 | ret finger protein-like 1 | Hs.648249 | chr22q12.2 | 127 | 0 |
| 209994_s_at | ABCB1 | ATP-binding cassette, sub-family B (MDR/TAP), member 1 | Hs.489033 | chr7q21.1 | 125 | 0 |
| 207227_x_at | RFPL2 | ret finger protein-like 2 | Hs.157427 | chr22q12.3 | 116 | 0 |
| 238218_at | LOC648473 | hypothetical protein LOC648473 | | | 112 | 0 |
| 214603_at | MAGEA2 | melanoma antigen family A, 2 | Hs.169246 | chrXq28 | 111 | 0 |
| 217590_s_at | TRPA1 | transient receptor potential cation channel, subfamily A, member 1 | Hs.137674 | chr8q13 | 110 | 0 |
| 208312_s_at | PRAMEF1 | PRAME family member 1 | Hs.104991 | chr1p36.21 | 109 | 0 |
| 223866_at | ARMC2 | armadillo repeat containing 2 | | chr6q21 | 106 | 0 |
| 216001_at | LOC390999 | PRAME family member 12 | Hs.156406 | chr1p36.21 | 106 | 0 |

Table 1. Cont.

| Probesets | Gene Name | Gene Title | UniGene | Chromosomal Location | Fold change | FDR (%) |
|--------------|-----------|--|-----------|----------------------|-------------|---------|
| 213228_at | PDE8B | phosphodiesterase 8B | Hs.584830 | chr5q14.1 | 104 | 0 |
| 1552807_a_at | SIGLEC10 | sialic acid binding Ig-like lectin 10 | Hs.284813 | chr19q13.3 | 104 | 0 |
| 236205_at | Hs.13188 | similar to ATP-binding cassette, sub-family C, member 6 | Hs.13188 | chr16p12.3 | 104 | 0 |
| 209942_x_at | MAGEA3 | melanoma antigen family A, 3 | Hs.417816 | chrXq28 | 100 | 0 |
| 226271_at | GDAP1 | ganglioside-induced differentiation-associated protein 1 | Hs.168950 | chr8q21.11 | 98 | 0 |
| 240031_at | AA994467 | Baculoviral IAP repeat-containing 2 | Hs.503704 | chr11q22 | 98 | 0 |
| 209570_s_at | D45234E | DNA segment on chromosome 4 (unique) 234 expressed sequence | Hs.518595 | chr4p16.3 | 98 | 0 |
| 206207_at | CLC | Charcot-Leyden crystal protein | Hs.889 | chr19q13.1 | 96 | 0 |
| 230626_at | TSPAN12 | tetraspanin 12 | Hs.16529 | chr7q31.31 | 93 | 0 |
| 216034_at | SUHW1 | suppressor of hairy wing homolog 1 (Drosophila) | Hs.178665 | chr22q11.22 | 89 | 0 |
| 231756_at | ZP4 | zona pellucida glycoprotein 4 | Hs.136241 | chr1q43 | 89 | 0 |
| 202388_at | RGS2 | regulator of G-protein signalling 2, 24 kDa | Hs.78944 | chr1q31 | 85 | 0 |
| 205747_at | CBLN1 | cerebellin 1 precursor | Hs.458423 | chr16q12.1 | 84 | 0 |
| 230753_at | LOC197135 | hypothetical LOC197135 | Hs.11594 | chr15q21.1 | 83 | 0 |
| 236117_at | Hs.42747 | Transcribed locus | Hs.42747 | | 83 | 0 |
| 1556834_at | Hs.562766 | CDNA clone IMAGE:5296106 | Hs.562766 | | 83 | 0 |
| 209278_s_at | TFPI2 | tissue factor pathway inhibitor 2 | Hs.438231 | chr7q22 | 81 | 0 |
| 240318_at | AFMID | Arylformamidase | Hs.558614 | chr17q25.3 | 80 | 0 |
| 1557257_at | BCL10 | B-cell CLL/lymphoma 10 | Hs.193516 | chr1p22 | 80 | 0 |
| 236504_x_at | C6orf52 | chromosome 6 open reading frame 52 | Hs.61389 | chr6p24.1 | 80 | 0 |
| 204438_at | MRC1 | mannose receptor, C type 1 | Hs.75182 | chr10p12.33 | 80 | 0 |
| 1559108_at | VPS53 | Vacuolar protein sorting 53 (S. cerevisiae) | Hs.461819 | chr17p13.3 | 79 | 0 |
| 210180_s_at | SFRS10 | splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila) | Hs.533122 | chr3q26.2-q27 | 77 | 0 |
| 214960_at | API5 | apoptosis inhibitor 5 | Hs.435771 | chr11p12-q12 | 77 | 0 |
| 232692_at | TDRD6 | tudor domain containing 6 | Hs.40510 | chr6p12.3 | 76 | 0 |
| 240731_at | LOC441316 | | | | 76 | 0 |
| 230697_at | BBS5 | Bardet-Biedl syndrome 5 | Hs.233398 | chr2q31.1 | 75 | 0 |
| 244206_at | ANUBL1 | AN1, ubiquitin-like, homolog (Xenopus laevis) | Hs.89029 | chr10q11.21 | 75 | 0 |
| 222921_s_at | HEY2 | hairy/enhancer-of-split related with YRPW motif 2 | Hs.144287 | chr6q21 | 74 | 0 |
| 1557146_a_at | FLJ32252 | hypothetical protein FLJ32252 | Hs.250557 | chr16p13.3 | 73 | 0 |
| 241382_at | PCP4L1 | Purkinje cell protein 4 like 1 | Hs.433150 | chr1q23.3 | 73 | 0 |
| 226811_at | FAM46C | family with sequence similarity 46, member C | Hs.356216 | chr1p12 | 73 | 0 |
| 44783_s_at | HEY1 | hairy/enhancer-of-split related with YRPW motif 1 | Hs.234434 | chr8q21 | 73 | 0 |
| 239061_at | TPRXL | tetra-peptide repeat homeobox-like | Hs.638296 | chr3p25.1 | 72 | 0 |
| 223562_at | PARVG | parvin, gamma | Hs.565777 | chr22q13.2-q13 | 69 | 0 |
| 219352_at | HERC6 | hect domain and RLD 6 | Hs.529317 | chr4q22.1 | 69 | 0 |
| 1553697_at | C1orf96 | chromosome 1 open reading frame 96 | Hs.585011 | chr1q42.13 | 68 | 0 |
| 1568924_a_at | FLJ35834 | hypothetical protein FLJ35834 | Hs.159650 | chr7q31.32 | 68 | 0 |
| 221314_at | GDF9 | growth differentiation factor 9 | Hs.25022 | chr5q31.1 | 67 | 0 |
| 228737_at | C20orf100 | chromosome 20 open reading frame 100 | Hs.26608 | chr20q13.12 | 66 | 0 |
| 240070_at | VSIG9 | V-set and immunoglobulin domain containing 9 | Hs.421750 | chr3q13.31 | 66 | 0 |
| 231448_at | Tenr | testis nuclear RNA-binding protein | Hs.518957 | chr4q27 | 65 | 0 |
| 214612_x_at | MAGEA6 | melanoma antigen family A, 6 | Hs.441113 | chrXq28 | 64 | 0 |
| 206696_at | GPR143 | G protein-coupled receptor 143 | Hs.74124 | chrXp22.3 | 62 | 0 |
| 205551_at | SV2B | synaptic vesicle glycoprotein 2B | Hs.592018 | chr15q26.1 | 61 | 0 |
| 219686_at | STK32B | serine/threonine kinase 32B | Hs.133062 | chr4p16.2-p16.1 | 61 | 0 |

Table 1. Cont.

| Probesets | Gene Name | Gene Title | UniGene | Chromosomal Location | Fold change | FDR (%) |
|--------------|-----------|---|-----------|----------------------|-------------|---------|
| 230645_at | FRMD3 | FERM domain containing 3 | Hs.127535 | chr9q21.32 | 60 | 0 |
| 1555396_s_at | LOC340602 | similar to CG32656-PA | Hs.97053 | chrXp11.22 | 59 | 0 |
| 237464_at | IMAA | SLC7A5 pseudogene | Hs.448808 | chr16p12.2 | 58 | 0 |
| 212158_at | SDC2 | syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, fibroglycan) | Hs.1501 | chr8q22-q23 | 57 | 0 |
| 220657_at | KLHL11 | kelch-like 11 (Drosophila) | Hs.592134 | chr17q21.2 | 57 | 0 |
| 223883_s_at | STK31 | serine/threonine kinase 31 | Hs.309767 | chr7p15.3 | 57 | 0 |
| 222925_at | DCDC2 | doublecortin domain containing 2 | Hs.61345 | chr6p22.1 | 56 | 0 |
| 210148_at | AF305239 | homeodomain interacting protein kinase 3 | Hs.201918 | chr11p13 | 56 | 0 |

doi:10.1371/journal.pone.0039306.t001

embryo development is arrested at the two-cell stage [35]. Remarkably, many genes of the day 3 signature belong to the Melanoma Antigen family and the Ret finger protein-like family. Most of their functions remain largely unknown, but some of them are thought to regulate, respectively, placenta and early embryo development [36,37]. Mouse data suggest that two other day 3 embryo-specific genes (*MBD3L2* and *ZSCAN4*) might regulate early embryo development. In mouse embryos, *MBD3L2* expression coincides with EGA [38] and *ZSCAN4* (zinc finger and SCAN domain containing 4) is important for the progression from the 2-cell to 4-cell stage [39]. *ZSCAN4* plays also a key role in defying cellular senescence and maintaining a normal karyotype during propagation of embryonic stem cells in culture [40]. Additionally, the expression levels of *DPPA5*, *DPPA2* and the stemness factor *NANOG* were much higher in day 3 embryos than in TE samples. The reciprocal pattern of expression of *Nanog* and the transcription factors *Gata6* and *Cdx2* in the mouse morula suggests that *Nanog* might determine ICM pluripotency by repressing *Gata6* and *Cdx2*, which are implicated in the extra-embryonic lineage specification [41].

Our transcriptome analysis also shows that the TE molecular signature includes many genes that are annotated as “membrane”, demonstrating a strong bias towards genes involved in cell-to-cell communication processes. Conversely, genes specifically expressed by day 3 embryos are largely “nuclear”. Additionally, we categorized the genes that were up-regulated during the MII-day 3 transition according to their molecular and cellular function using the GO annotations and found that they were mainly associated with nuclear localization. This is in line with previously published data showing that proteins produced by the most up-regulated genes during the MII-day 2 embryo transition are mainly localized in the nucleus [11] and that hESC-specific genes are significantly depleted in extracellular signaling components [7]. One assumption that can be inferred from these findings is that the determinants of the MII-embryo transition and pluripotency may be regulated by intrinsic factors.

Apoptotic cell death has been observed in human and other mammalian pre-implantation embryos [42]. The expression profile of apoptosis-related genes in day 3 embryos suggests that the balance between anti- (*BCL2L10* and *BIRC2*) and pro-apoptotic factors (*BCL2L11* and *BIK*) might be critical at this stage of development. As the onset of EGA occurs at day 3 post-fertilization in humans, embryos that fail to accurately activate their genome might be committed to death by default. In contrast to mouse blastocysts where apoptosis occurs predominantly in

ICM cells [43], apoptotic nuclei have been detected in both ICM and TE cells in human blastocysts [44]. Accordingly, we show that some molecular actors of apoptosis signaling are up-regulated in human TE cells (i.e. *Caspase 6*, *MCL-1*).

The expression of some DNA repair genes has been detected in mammalian embryos at different stages of development [45]. Our data show that two “DNA damage sensor” genes (*RFC1* and *PCNA1*) and two “base excision repair” genes (*UNG* and *UNG2* (now named as *CCNO*)) are up-regulated in human day 3 embryos, in line with previous works [46], and three “Double strand break repair” genes (*BRCA1*, *XRCC5* and *XRCC6*) are over-expressed in TE cells. In homozygous *Brcal*⁵⁻⁶ mouse mutants, in which exons 5 and 6 of *Brcal* were deleted, the development of the extra-embryonic region was abnormal and diploid trophoblast cells were absent [47]. This may indicate that the “Double strand break repair” activity may be important for TE specification.

Epigenetic mechanisms, including DNA methylation, are key elements for controlling gene expression during the embryo-TE transition. In mouse blastocysts, DNA methyltransferase expression is restricted to the ICM, in which nuclei are highly methylated [48], whereas in human and bovine blastocysts, DNA methylation is higher in TE than ICM cells [49]. Here we report a strong expression of DNA (cytosine-5) methyltransferases (*DNMT3A*, *DNMT3B*, *DNMT1* and *DNMT3L*) in human TE cells (Figure 5). *DNMT3A* and *DNMT3B* are de novo enzymes that establish methylation patterns. *DNMT1* is a maintenance enzyme involved in preserving already acquired methylation patterns. *DNMT3L* lacks a catalytic domain, but can interact with the de novo enzymes [50], stimulating their activity [51]. Comparison with other samples including MII oocytes and hESCs suggests that *DNMT3L* is specifically up-regulated in TE cells (Figure S4). However, DNA methylation levels have been described to be globally low in extra-embryonic tissues in both mouse and human embryos [52,53]. In these tissues, DNA (cytosine-5) methyltransferase enzymes are expressed only transiently and do not contribute to adult tissues maintenance, thus long-term epigenetic reprogramming may not be critical for extra-embryonic tissues. Moreover, the high expression of different epigenetic regulators in human TE cells could be a consequence of *in vitro* embryo culture. Studies in animal models have demonstrated that under certain *in vitro* culture conditions, DNA methylation profiles can be altered [54]. In another hand, the association between *in vitro* culture conditions during assisted reproduction and increased risk of some epigenetic disorders has been reported, clearly indicating that epigenetic deregulation must be considered when examining in

Table 2. List of the 100 genes with the highest fold change in TE samples in comparison to day 3 embryos.

| Probesets | Gene Name | Gene Title | UniGene | Chromosomal Location | Fold Change | FDR (%) |
|-------------|-----------|--|-----------|----------------------|-------------|---------|
| 205980_s_at | ARHGAP8 | Rho GTPase activating protein 8/PRR5-ARHGAP8 fusion | | chr22q13.31 | 514 | 0 |
| 218237_s_at | SLC38A1 | solute carrier family 38, member 1 | Hs.533770 | chr12q13.11 | 469 | 0 |
| 201596_x_at | KRT18 | keratin 18 | Hs.406013 | chr12q13 | 445 | 0 |
| 204515_at | HSD3B1 | hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Hs.364941 | chr1p13.1 | 383 | 0 |
| 227048_at | LAMA1 | laminin, alpha 1 | Hs.270364 | chr18p11.31 | 372 | 0 |
| 34260_at | KIAA0683 | TEL2, telomere maintenance 2, homolog (S. cerevisiae) | Hs.271044 | chr16p13.3 | 361 | 0 |
| 224348_s_at | AF116709 | | | | 341 | 0 |
| 223168_at | RHOU | ras homolog gene family, member U | Hs.647774 | chr1q42.11-q42.3 | 310 | 0 |
| 204158_s_at | TCIRG1 | T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 | Hs.495985 | chr11q13.2 | 283 | 0 |
| 212203_x_at | IFITM3 | interferon induced transmembrane protein 3 (1-8 U) | Hs.374650 | chr11p15.5 | 279 | 0 |
| 242705_x_at | Hs.592928 | Full length insert cDNA clone YT86E01 | Hs.592928 | | 277 | 0 |
| 204351_at | S100P | S100 calcium binding protein P | Hs.2962 | chr4p16 | 262 | 0 |
| 201650_at | KRT19 | keratin 19 | | chr17q21.2 | 260 | 0 |
| 229125_at | ANKRD38 | ankyrin repeat domain 38 | Hs.283398 | chr1p31.3 | 238 | 0 |
| 224646_x_at | H19 | H19, imprinted maternally expressed untranslated mRNA | Hs.533566 | chr11p15.5 | 208 | 0 |
| 221538_s_at | PLXNA1 | plexin A1 | Hs.432329 | chr3q21.3 | 204 | 0 |
| 210381_s_at | CCKBR | cholecystokinin B receptor | Hs.203 | chr11p15.4 | 196 | 0 |
| 217853_at | TNS3 | tensin 3 | Hs.520814 | chr7p12.3 | 194 | 0 |
| 209771_x_at | CD24 | CD24 molecule | Hs.644105 | chr6q21 | 194 | 0 |
| 210201_x_at | BIN1 | bridging integrator 1 | Hs.193163 | chr2q14 | 156 | 0 |
| 224579_at | Hs.592612 | solute carrier family 38, member 1 | Hs.533770 | chr12q13.11 | 147 | 0 |
| 204720_s_at | DNAJC6 | DnaJ (Hsp40) homolog, subfamily C, member 6 | Hs.647643 | chr1pter-q31.3 | 135 | 0 |
| 212444_at | Hs.632997 | CDNA clone IMAGE:6025865 | Hs.632997 | | 135 | 0 |
| 203767_s_at | STS | steroid sulfatase (microsomal), arylsulfatase C, isozyme S | Hs.522578 | chrXp22.32 | 135 | 0 |
| 215729_s_at | VGLL1 | vestigial like 1 (Drosophila) | Hs.496843 | chrXq26.3 | 134 | 0 |
| 227241_at | MUC15 | mucin 15, cell surface associated | Hs.407152 | chr11p14.3 | 133 | 0 |
| 204121_at | GADD45G | growth arrest and DNA-damage-inducible, gamma | Hs.9701 | chr9q22.1-q22.2 | 125 | 0 |
| 212077_at | CALD1 | caldesmon 1 | Hs.490203 | chr7q33 | 122 | 0 |
| 201787_at | FBLN1 | fibulin 1 | Hs.24601 | chr22q13.31 | 121 | 0 |
| 202286_s_at | TACSTD2 | tumor-associated calcium signal transducer 2 | Hs.23582 | chr1p32-p31 | 109 | 0 |
| 218571_s_at | CHMP4A | chromatin modifying protein 4A | Hs.279761 | chr14q12 | 108 | 0 |
| 205829_at | HSD17B1 | hydroxysteroid (17-beta) dehydrogenase 1 | Hs.50727 | chr17q11-q21 | 108 | 0 |
| 205093_at | PLEKHA6 | pleckstrin homology domain containing, family A member 6 | Hs.253146 | chr1q32.1 | 105 | 0 |
| 209735_at | ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Hs.480218 | chr4q22 | 104 | 0 |
| 213050_at | COBL | cordon-bleu homolog (mouse) | Hs.99141 | chr7p12.1 | 97 | 0 |
| 205081_at | CRIP1 | cysteine-rich protein 1 (intestinal) | Hs.122006 | chr14q32.33 | 93 | 0 |
| 209262_s_at | NR2F6 | nuclear receptor subfamily 2, group F, member 6 | Hs.466148 | chr19p13.1 | 91 | 0 |
| 203438_at | STC2 | stanniocalcin 2 | Hs.233160 | chr5q35.2 | 90 | 0 |
| 214285_at | FABP3 | fatty acid binding protein 3, muscle and heart | Hs.584756 | chr1p33-p32 | 89 | 0 |
| 209369_at | ANXA3 | annexin A3 | Hs.480042 | chr4q13-q22 | 89 | 0 |

Table 2. Cont.

| Probesets | Gene Name | Gene Title | UniGene | Chromosomal Location | Fold Change | FDR (%) |
|--------------|-----------|---|-----------|----------------------|-------------|---------|
| 209723_at | SERPINB9 | serpin peptidase inhibitor, clade B (ovalbumin), member 9 | Hs.104879 | chr6p25 | 88 | 0 |
| 209921_at | SLC7A11 | solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 | Hs.390594 | chr4q28-q32 | 87 | 0 |
| 216604_s_at | SLC7A8 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 8 | Hs.632348 | chr14q11.2 | 86 | 0 |
| 228949_at | GPR177 | G protein-coupled receptor 177 | Hs.647659 | chr1p31.3 | 84 | 0 |
| 202007_at | NID1 | nidogen 1 | Hs.356624 | chr1q43 | 84 | 0 |
| 209513_s_at | HSDL2 | hydroxysteroid dehydrogenase like 2 | Hs.59486 | chr9q32 | 83 | 0 |
| 225520_at | MTHFD1L | methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like | Hs.591343 | chr6q25.1 | 82 | 0 |
| 202023_at | EFNA1 | ephrin-A1 | Hs.516664 | chr1q21-q22 | 81 | 0 |
| 205710_at | LRP2 | low density lipoprotein-related protein 2 | Hs.470538 | chr2q24-q31 | 78 | 0 |
| 217764_s_at | RAB31 | RAB31, member RAS oncogene family | Hs.99528 | chr18p11.3 | 77 | 0 |
| 225516_at | SLC7A2 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 | Hs.448520 | chr8p22-p21.3 | 77 | 0 |
| 200832_s_at | SCD | stearoyl-CoA desaturase (delta-9-desaturase) | Hs.558396 | chr10q23-q24 | 76 | 0 |
| 202418_at | YIF1A | Yip1 interacting factor homolog A (S. cerevisiae) | Hs.446445 | chr11q13 | 74 | 0 |
| 200872_at | S100A10 | S100 calcium binding protein A10 | Hs.143873 | chr1q21 | 74 | 0 |
| 209603_at | GATA3 | GATA binding protein 3 | Hs.524134 | chr10p15 | 73 | 0 |
| 1555832_s_at | KLF6 | Kruppel-like factor 6 | Hs.4055 | chr10p15 | 73 | 0 |
| 202737_s_at | LSM4 | LSM4 homolog, U6 small nuclear RNA associated (S. cerevisiae) | Hs.515255 | chr19p13.11 | 71 | 0 |
| 226604_at | TMTC3 | transmembrane and tetratricopeptide repeat containing 3 | Hs.331268 | chr12q21.32 | 71 | 0 |
| 220139_at | DNMT3L | DNA (cytosine-5-)-methyltransferase 3-like | Hs.592165 | chr21q22.3 | 70 | 0 |
| 206269_at | GCM1 | glial cells missing homolog 1 (Drosophila) | Hs.28346 | chr6p21-p12 | 69 | 0 |
| 203743_s_at | TDG | thymine-DNA glycosylase | Hs.584809 | chr12q24.1 | 69 | 0 |
| 219010_at | C1orf106 | chromosome 1 open reading frame 106 | Hs.518997 | chr1q32.1 | 69 | 0 |
| 225021_at | ZNF532 | zinc finger protein 532 | Hs.529023 | chr18q21.32 | 69 | 0 |
| 205524_s_at | HAPLN1 | hyaluronan and proteoglycan link protein 1 | Hs.591758 | chr5q14.3 | 68 | 0 |
| 206548_at | FLJ23556 | hypothetical protein FLJ23556 | | chr10q26.11 | 66 | 0 |
| 202800_at | SLC1A3 | solute carrier family 1 (glial high affinity glutamate transporter), member 3 | Hs.481918 | chr5p13 | 65 | 0 |
| 229699_at | Hs.61558 | CDNA FLJ45384 fis, clone BRHIP3021987 | Hs.61558 | | 65 | 0 |
| 229830_at | Hs.376032 | Transcribed locus | Hs.535898 | | 65 | 0 |
| 202308_at | SREBF1 | sterol regulatory element binding transcription factor 1 | Hs.592123 | chr17p11.2 | 64 | 0 |
| 203219_s_at | APRT | adenine phosphoribosyltransferase | Hs.28914 | chr16q24 | 64 | 0 |
| 225078_at | EMP2 | epithelial membrane protein 2 | Hs.531561 | chr16p13.2 | 64 | 0 |
| 218180_s_at | EPS8L2 | EPS8-like 2 | Hs.55016 | chr11p15.5 | 63 | 0 |
| 201440_at | DDX23 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 | Hs.130098 | chr12q13.12 | 62 | 0 |
| 201236_s_at | BTG2 | BTG family, member 2 | Hs.519162 | chr1q32 | 62 | 0 |
| 218721_s_at | C1orf27 | chromosome 1 open reading frame 27 | Hs.371210 | chr1q25 | 61 | 0 |
| 223062_s_at | PSAT1 | phosphoserine aminotransferase 1 | Hs.494261 | chr9q21.2 | 61 | 0 |
| 201613_s_at | AP1G2 | adaptor-related protein complex 1, gamma 2 subunit | Hs.343244 | chr14q11.2 | 60 | 0 |
| 211986_at | AHNAK | AHNAK nucleoprotein (desmoyokin) | Hs.502756 | chr11q12.2 | 60 | 0 |
| 223449_at | SEMA6A | sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A | Hs.156967 | chr5q23.1 | 60 | 0 |
| 1567107_s_at | TPM3 | tropomyosin 4 | Hs.631618 | chr19p13.1 | 58 | 0 |

Table 2. Cont.

| Probesets | Gene Name | Gene Title | UniGene | Chromosomal Location | Fold Change | FDR (%) |
|--------------|-----------|---|-----------|----------------------|-------------|---------|
| 208659_at | CLIC1 | chloride intracellular channel 1 | Hs.414565 | chr6p22.1-p21.2 | 57 | 0 |
| 202546_at | VAMP8 | vesicle-associated membrane protein 8 (endobrevin) | Hs.534373 | chr2p12-p11.2 | 57 | 0 |
| 227042_at | LOC150223 | hypothetical protein LOC150223 | Hs.355952 | chr22q11.21 | 57 | 0 |
| 202625_at | LYN | v-yes-1 Yamaguchi sarcoma viral related oncogene homolog | Hs.651186 | chr8q13 | 56 | 0 |
| 235436_at | BE503800 | | | | 55 | 0 |
| 223839_s_at | Hs.597496 | PRO1933 | Hs.597496 | | 55 | 0 |
| 202830_s_at | SLC37A4 | solute carrier family 37 (glycerol-6-phosphate transporter), member 4 | Hs.132760 | chr11q23.3 | 54 | 0 |
| 228834_at | TOB1 | transducer of ERBB2, 1 | Hs.649528 | chr17q21 | 54 | 0 |
| 210589_s_at | GBA | glucosidase, beta; acid (includes glucosylceramidase) | Hs.282997 | chr1q21 | 53 | 0 |
| 208683_at | CAPN2 | calpain 2, (m/II) large subunit | Hs.350899 | chr1q41-q42 | 53 | 0 |
| 201428_at | CLDN4 | claudin 4 | Hs.647036 | chr7q11.23 | 52 | 0 |
| 217775_s_at | RDH11 | retinol dehydrogenase 11 (all-trans/9-cis/11-cis) | Hs.226007 | chr14q24.1 | 51 | 0 |
| 208613_s_at | FLNB | filamin B, beta (actin binding protein 278) | Hs.476448 | chr3p14.3 | 49 | 0 |
| 230204_at | AU144114 | | | | 49 | 0 |
| 209710_at | GATA2 | GATA binding protein 2 | Hs.367725 | chr3q21.3 | 48 | 0 |
| 215464_s_at | TAX1BP3 | Tax1 (human T-cell leukemia virus type I) binding protein 3 | Hs.12956 | chr17p13 | 47 | 0 |
| 1559266_s_at | FLJ45187 | hypothetical protein LOC387640 | Hs.350848 | chr10p12.31 | 47 | 0 |
| 202090_s_at | UOCR | ubiquinol-cytochrome c reductase, 6.4 kDa subunit | Hs.534521 | chr19p13.3 | 47 | 0 |
| 209652_s_at | PGF | placental growth factor, vascular endothelial growth factor-related protein | Hs.252820 | chr14q24-q31 | 47 | 0 |
| 232164_s_at | EPPK1 | epiplakin 1 | Hs.200412 | chr8q24.3 | 47 | 0 |

doi:10.1371/journal.pone.0039306.t002

vitro fertilized embryos. Our findings suggest that epigenetic modifiers cooperate with transcription factors and DNA repair genes to regulate the whole gene expression profile in TE cells (Figure 5). Disruption of this epigenetic regulatory circuit might lead to alterations of the normal physiological functions. Therefore, a comprehensive elucidation of this regulatory network would be highly beneficial for understanding TE anomalies and for improving assisted reproduction procedures. Moreover, a better knowledge on the TE-specific genes and the transcriptional networks operative in TE cells and day 3 embryos might lead to the identification of new biomarkers that might be used as diagnostic tools to monitor the health, viability and competence of embryos in assisted reproduction programs.

Limitations

As the day 3 embryos and the day 5 embryos used to isolate TE cells were donated from infertile women who underwent IVF treatments, the gene expression profiles could be influenced by the controlled ovarian stimulation (COS) carried out during IVF and thus they might not completely reflect the physiological situation under natural cycles. Moreover, due to the bioethics law that regulates the research on human embryos in France, the number of embryos donated for research is smaller. In view of these limitations, we optimized our technique to obtain transcriptome data for each single embryo and trophectoderm sample, respectively.

Materials and Methods

Specimen Collection and Processing


Human day 3 (post-fertilization) embryos and day 5 blastocysts were donated for research by infertile couples undergoing IVF treatment. All patients signed informed consent forms and the protocol for collecting human embryos and TE was approved by the Ethical Committee of the French National Agency of Biomedicine.

Day 3 embryos. 9 embryos from 6 different couples were used for microarray analyses ($n=6$) and qRT-PCR validation ($n=3$). Day 3 embryos were all 6–8 cells with <20% fragmentation. Each embryo was individually transferred in a tube containing extraction buffer and frozen at -80°C for subsequent RNA extraction.


Trophectoderm biopsy. 8 day 5 blastocysts were used for TE isolation for microarray analyses ($n=5$) and qRT-PCR validation ($n=3$). Blastocysts were fully expanded with a well-defined ICM and TE was scored according to Gardner [55]. After removal of the zona pellucida, TE was mechanically dissected from ICM. All TE samples were immediately transferred in tubes containing RLT lysis buffer and frozen at -80°C .

Mature MII oocytes and hESCs. After informed consent, unfertilized MII oocytes were collected 24 or 48 hours post-insemination as previously described [56]. Briefly, three pools of 16 MII oocytes (6 patients), 21 MII oocytes (8 patients) and 24 MII

A



B



generate suitable quantity of labeled cRNA for hybridization to HG-U133 plus 2.0 GeneChip arrays (Affymetrix, Santa Clara, CA, USA) as described in [9] and following the standard Affymetrix instructions. Briefly, RNA was amplified from individual human embryos using the RiboAmp[®] HS Kit according to manufacturer's instructions (Arcturus Bioscience). During the first strand synthesis reaction, cDNA that incorporates a T7 promoter sequence is produced. This cDNA was then used as a template for the in vitro-transcription reaction driven by the T7 promoter to synthesize antisense RNA (aRNA), which was used as input for the second round of amplification. cRNA was then transcribed into cDNA and the T7 promoter was used to drive the second round of in vitro transcription. The double-stranded cDNA was then subjected to three rounds of linear amplification. The amplified aRNA was labeled with biotin using the Turbo Labeling Kit (Arcturus) and fragmented. Finally, fifteen micrograms of each labeled sample were hybridized to the HG-U133plus2 GeneChip array (Affymetrix). The microarray data were obtained in agreement with the Minimal Information about Microarray Experiment (MIAME) recommendations [58]. All data are accessible at the US National Center for Biotechnology Information, Gene Expression Omnibus (GEO) repository <http://www.ncbi.nlm.nih.gov/geo> through the provisional accession series number GSE33025.

Data Processing and Visualization

After image processing using the Affymetrix Microarray Suite 5.0, the cell files were analyzed using the Affymetrix Expression Console software and normalized with the MAS5 algorithm by scaling each array to a target value of 100 using the global scaling method to obtain an intensity value signal for each probe set. Gene annotation was performed using NetAffx (<http://www.affymetrix.com>; March 2009). Genes with significant differential expression profiles were identified using the two-class Significance Analysis of Microarray (SAM) algorithm (<http://www-stat.stanford.edu/~tibs/SAM/>) with the Wilcoxon test and sample label permutation ($n = 300$). Briefly, the algorithm assigns a score to each gene based on differences in expression between conditions relative to the standard deviation of repeated measurements. The false discovery rate (FDR) is determined using permutations of the repeated measurements to estimate the percentage of genes identified by chance. The algorithm was applied to each dataset separately using $FDR < 1\%$. Subsequently, only the genes marked as significantly up-regulated or down-regulated were considered as differentially expressed in TE or embryos compared with the other samples. For hierarchical clustering, data were log-transformed, median-centered and processed with the CLUSTER and TREEVIEW software packages [59]. To cluster the samples according to the similarity of their gene expression patterns, we performed an unsupervised principal component analysis (PCA) with the RAGE bioinformatics platform [<http://rage.montp.inserm.fr/>] to project samples onto three-dimensional spaces that were further visualized to see the constellation of all samples using all the detected genes. The expression of selected genes in the panel of samples that includes germinal, stem cells and adult tissues, were retrieved through our "Amazonia!" database (<http://amazonia.montp.inserm.fr/>). The Ingenuity Pathways Analysis (IPA) system (Ingenuity Systems, Redwood City, CA, USA) was used to identify networks related to the genes that were differentially expressed in day 3 embryos and TE samples.

Gene Ontologies (GO) Classification

Gene Ontology (GO) annotation analysis was carried out using the Fatigo+ tool <http://babelomics.bioinfo.cipf.es> [60] to identify

biologically relevant themes among the genes that were differentially expressed in day 3 embryos and TE cells. Briefly, Fatigo+ performs a functional enrichment analysis by comparing two lists of genes by means of the Fisher's Exact Test. Gene modules used in the test are defined in different ways that include functional criteria (GO, KEGG, Biocarta, etc.). Also user-defined gene modules can be imported and used for functional enrichment.

Validation of Microarray Data by Quantitative RT-PCR Amplification

Gene expression profiles derived from microarray analyses were confirmed quantitatively by real-time qRT-PCR analysis using RNAs from three TE samples, three day 3 embryos, three MII oocytes and three hESC samples. The primer sequences are shown in Table S3. Briefly, cDNA was reverse transcribed following the manufacturer's instructions using 500 ng of total RNA in a 20 μ l reaction that contained Superscript II (Invitrogen), oligo dT primer, dNTP mixture, MgCl₂ and RNase inhibitor. Aliquots of cDNA (1/25 of the RT reaction) were diluted in 50 μ l reaction volume. Q-PCR was performed using a LightCycler 480 apparatus with the LC480 SYBR Green I Master kit (Roche Diagnostics, Mannheim, Germany) containing 2 μ l cDNA and 0.6 mMol primers in a total volume of 10 μ l. After 10 min of activation at 95°C, cycling conditions were 10 s at 95°C, 30 s at 63°C and 1 s at 72°C for 50 cycles. Gene expression levels were normalized to *GAPDH* using the following formula $100/2^{\Delta\Delta Ct}$ where $\Delta\Delta Ct = \Delta Ct_{unknown} - \Delta Ct_{positive\ control}$. Statistical comparisons were carried out using the Student's *t* test and the SPSS software. *P* values less than or equal to 0.05 were considered significant.

Supporting Information

Figure S1 Scatter plots showing the comparative distribution of transcripts in mature MII oocytes, day 3 embryos, TE and hESC samples. Each sample was plotted against all the other samples to visualize expression variations. The blue areas highlight a greater than two-fold gene expression difference (up-regulated) between the X-axis and Y-axis samples. The orange areas indicate a greater than two-fold gene expression difference (down-regulated) between the X-axis and Y-axis samples. The yellow areas highlight a 0.5- to 2-fold gene expression difference between the X-axis and Y-axis samples. For each couple of samples, the Pearson's correlation coefficient was computed (*r*). (TIF)

Figure S2 Quantitative RT-PCR validation of the microarray results: All qRT-PCR results were normalized to the expression of *GAPDH* in each sample and are the mean \pm SEM of individual day 3 embryos ($n = 3$), TE ($n = 3$), pooled MII oocyte ($n = 3$) and hESC ($n = 3$) samples analyzed in duplicate. * $P < 0.05$ was considered significant (TIF)

Figure S3 IPA results showing the network of DNA repair genes that are up-regulated in TE samples from day 5 human blastocysts and day 3 embryos. (TIF)

Figure S4 Venn diagram representing the number of genes in each comparison and the overlaps between the three main comparison groups. The day 3 embryo/MIIOocyte/hESC signatures were defined as the intersection of the day 3 embryo signature (genes over-expressed in day3 embryos compared with TE samples; 1714 genes), the MII oocytes

signature (genes over-expressed in MII oocytes compared with TE cells; 4444 genes) and the hESC signature (genes up-regulated in hESC compared to TE samples, 5502 genes). The TE/MII oocyte/hESC signature were defined as the intersection of the TE signature (genes over-expressed in TE compared with day 3 embryos; 2196 genes), the MII oocyte signature (genes over-expressed in MII oocytes compared with day 3 embryos; 3198 genes) and the hESC signature (genes over-expressed in hESCs compared with day 3 embryos; 8584 genes). The comparison between categories were generated by using the SAM software with a fold change ≥ 2 and FDR $< 1\%$.

(TIF)

Figure S5 Expression of selected genes, which were up-regulated either in TE cells (*HSD3B1*, *HSD17B1*, *FDX1*, *PTGS* and *DNMT3L*) or day 3 embryos (*NANOG*, *MBD3L2*, *ZSCAN4*, *RFPL2* and *DPPA2*), and of beta-Actin in the panel of samples that includes MII oocytes and hESCs using the Amazonia! gene atlas explorer (<http://www.amazonia.transcriptome.eu>). Abbreviations: hESC, human embryonic stem cell; hiPS, human induced pluripotent stem cells; TE, Trophectoderm; hFF, human foreskin fibroblasts; CNS, central nervous system; DT, digestive tract; H & L, Heart and muscle; HEMATO, various hematopoietic tissues; End, Endometrium; PL, placenta.

(TIF)

Table S1 List of the 1,714 transcripts specific to the day 3 embryo molecular signature.

(XLS)

References

- Dobson AT, Raja R, Abeyta MJ, Taylor T, Shen S, et al. (2004) The unique transcriptome through day 3 of human preimplantation development. *Hum Mol Genet* 13: 1461–1470.
- Niakan KK, Han J, Pedersen RA, Simon C, Pera RA (2012) Human pre-implantation embryo development. *Development* 139: 829–841.
- Galan A, Montaner D, Poo ME, Valbuena D, Ruiz V, et al. (2010) Functional genomics of 5- to 8-cell stage human embryos by blastomere single-cell cDNA analysis. *PLoS One* 5: e13615.
- Home P, Ray S, Dutta D, Bronshteyn I, Larson M, et al. (2009) GATA3 is selectively expressed in the trophectoderm of peri-implantation embryo and directly regulates *Cdx2* gene expression. *J Biol Chem* 284: 28729–28737.
- Jones GM, Cram DS, Song B, Kokkali G, Pantos K, et al. (2008) Novel strategy with potential to identify developmentally competent IVF blastocysts. *Hum Reprod* 23: 1748–1759.
- Shalon D, Smith SJ, Brown PO (1996) A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. *Genome Res* 6: 639–645.
- Assou S, Le Carrouer T, Tondeur S, Strom S, Gabelle A, et al. (2007) A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. *Stem Cells* 25: 961–973.
- Assou S, Boumela I, Haouzi D, Anahory T, Dechaud H, et al. (2011) Dynamic changes in gene expression during human early embryo development: from fundamental aspects to clinical applications. *Hum Reprod Update* 17: 272–290.
- Assou S, Cerecedo D, Tondeur S, Pantesco V, Hovatta O, et al. (2009) A gene expression signature shared by human mature oocytes and embryonic stem cells. *BMC Genomics* 10: 10.
- Hamatani T, Carter MG, Sharov AA, Ko MS (2004) Dynamics of global gene expression changes during mouse preimplantation development. *Dev Cell* 6: 117–131.
- Zhang P, Zucchelli M, Bruce S, Hambiliki F, Stavreus-Evers A, et al. (2009) Transcriptome profiling of human pre-implantation development. *PLoS One* 4: e7844.
- Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, et al. (2005) Multiple-laboratory comparison of microarray platforms. *Nat Methods* 2: 345–350.
- Wang QT, Piotrowska K, Ciemerych MA, Milenkovic L, Scott MP, et al. (2004) A genome-wide study of gene activity reveals developmental signaling pathways in the preimplantation mouse embryo. *Dev Cell* 6: 133–144.
- Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005. *Mutat Res* 577: 275–283.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 122: 947–956.
- Darr H, Benvenisty N (2006) Factors involved in self-renewal and pluripotency of embryonic stem cells. *Handb Exp Pharmacol*: 1–19.
- Wu Z, Zhang W, Chen G, Cheng L, Liao J, et al. (2008) Combinatorial signals of activin/nodal and bone morphogenic protein regulate the early lineage segregation of human embryonic stem cells. *J Biol Chem* 283: 24991–25002.
- Bai Q, Assou S, Haouzi D, Ramirez JM, Monzo C, et al. (2011) Dissecting the First Transcriptional Divergence During Human Embryonic Development. *Stem Cell Rev*.
- Xu RH, Chen X, Li DS, Li R, Addicks GC, et al. (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. *Nat Biotechnol* 20: 1261–1264.
- Yagi R, Kohn MJ, Karavanova I, Kaneko KJ, Vullhorst D, et al. (2007) Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. *Development* 134: 3827–3836.
- Cheng YH, Aronow BJ, Hossain S, Trapnell B, Kong S, et al. (2004) Critical role for transcription factor AP-2alpha in human trophoblast differentiation. *Physiol Genomics* 18: 99–107.
- Adjaye J, Huntriss J, Herwig R, BenKahla A, Brink TC, et al. (2005) Primary differentiation in the human blastocyst: comparative molecular portraits of inner cell mass and trophectoderm cells. *Stem Cells* 23: 1514–1525.
- Daulhac L, Kowalski-Chauvel A, Pradayrol L, Vaysse N, Seva C (1999) Src-family tyrosine kinases in activation of ERK-1 and p85/p110-phosphatidylinositol 3-kinase by G/CCKB receptors. *J Biol Chem* 274: 20657–20663.
- Todisco A, Takeuchi Y, Urumov A, Yamada J, Stepan VM, et al. (1997) Molecular mechanisms for the growth factor action of gastrin. *Am J Physiol* 273: G891–898.
- Cayrol C, Clerc P, Bertrand C, Gigoux V, Portolan G, et al. (2006) Cholecystokinin-2 receptor modulates cell adhesion through beta 1-integrin in human pancreatic cancer cells. *Oncogene* 25: 4421–4428.
- Peng L, Payne AH (2002) AP-2 gamma and the homeodomain protein distal-less 3 are required for placental-specific expression of the murine 3 beta-hydroxysteroid dehydrogenase VI gene, *Hsd3b6*. *J Biol Chem* 277: 7945–7954.
- Aghajanova L, Hamilton A, Kwintkiewicz J, Vo KC, Giudice LC (2009) Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. *Biol Reprod* 80: 105–114.
- Kayes-Wandover KM, White PC (2000) Steroidogenic enzyme gene expression in the human heart. *J Clin Endocrinol Metab* 85: 2519–2525.

29. Marchand M, Horcajadas JA, Esteban FJ, McElroy SL, Fisher SJ, et al. (2011) Transcriptomic signature of trophoblast differentiation in a human embryonic stem cell model. *Biol Reprod* 84: 1258–1271.
30. Aghajanova L, Shen S, Rojas AM, Fisher SJ, Irwin JC, et al. (2011) Comparative Transcriptome Analysis of Human Trophectoderm and Embryonic Stem Cell-Derived Trophoblasts Reveal Key Participants in Early Implantation. *Biol Reprod*.
31. Suzuki N, Yamada T, Matsuoka K, Hiraoka N, Iwamaru Y, et al. (1999) Functional expressions of fins and M-CSF during trophoectodermal differentiation of human embryonal carcinoma cells. *Placenta* 20: 203–211.
32. Zhang P, Dixon M, Zucchelli M, Hambiliki F, Levkov L, et al. (2008) Expression analysis of the NLRP gene family suggests a role in human preimplantation development. *PLoS One* 3: e2755.
33. Hamatani T, Falco G, Carter MG, Akutsu H, Staggs CA, et al. (2004) Age-associated alteration of gene expression patterns in mouse oocytes. *Hum Mol Genet* 13: 2263–2278.
34. Ponsuksili S, Brunner RM, Goldammer T, Kuhn C, Walz C, et al. (2006) Bovine NALP5, NALP8, and NALP9 genes: assignment to a QTL region and the expression in adult tissues, oocytes, and preimplantation embryos. *Biol Reprod* 74: 577–584.
35. Tong ZB, Gold L, Pfeifer KE, Dorward H, Lee E, et al. (2000) Mater, a maternal effect gene required for early embryonic development in mice. *Nat Genet* 26: 267–268.
36. Jungbluth AA, Silva WA, Jr., Iversen K, Frosina D, Zaidi B, et al. (2007) Expression of cancer-testis (CT) antigens in placenta. *Cancer Immun* 7: 15.
37. Suzumori N, Burns KH, Yan W, Matzuk MM (2003) RFPL4 interacts with oocyte proteins of the ubiquitin-proteasome degradation pathway. *Proc Natl Acad Sci U S A* 100: 550–555.
38. Telford NA, Watson AJ, Schultz GA (1990) Transition from maternal to embryonic control in early mammalian development: a comparison of several species. *Mol Reprod Dev* 26: 90–100.
39. Falco G, Lee SL, Stanghellini I, Bassey UC, Hamatani T, et al. (2007) Zscan4: a novel gene expressed exclusively in late 2-cell embryos and embryonic stem cells. *Dev Biol* 307: 539–550.
40. Zalzman M, Falco G, Sharova LV, Nishiyama A, Thomas M, et al. (2010) Zscan4 regulates telomere elongation and genomic stability in ES cells. *Nature* 464: 858–863.
41. Rossant J (2004) Lineage development and polar asymmetries in the preimplantation mouse blastocyst. *Semin Cell Dev Biol* 15: 573–581.
42. Boumela I, Assou S, Aouacheria A, Haouzi D, Dechaud H, et al. (2011) Involvement of BCL2 family members in the regulation of human oocyte and early embryo survival and death: gene expression and beyond. *Reproduction* 141: 549–561.
43. Handyside AH, Hunter S (1984) A rapid procedure for visualising the inner cell mass and trophectoderm nuclei of mouse blastocysts in situ using polynucleotide-specific fluorochromes. *J Exp Zool* 231: 429–434.
44. Hardy K, Handyside AH, Winston RM (1989) The human blastocyst: cell number, death and allocation during late preimplantation development in vitro. *Development* 107: 597–604.
45. Jaroudi S, SenGupta S (2007) DNA repair in mammalian embryos. *Mutat Res* 635: 53–77.
46. Jaroudi S, Kakourou G, Cawood S, Doshi A, Ranieri DM, et al. (2009) Expression profiling of DNA repair genes in human oocytes and blastocysts using microarrays. *Hum Reprod* 24: 2649–2655.
47. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, et al. (1996) The tumor suppressor gene Brcal is required for embryonic cellular proliferation in the mouse. *Cell* 85: 1009–1023.
48. Watanabe D, Suetake I, Tada T, Tajima S (2002) Stage- and cell-specific expression of Dnmt3a and Dnmt3b during embryogenesis. *Mech Dev* 118: 187–190.
49. Fulka H, Mrazek M, Tepla O, Fulka J, Jr. (2004) DNA methylation pattern in human zygotes and developing embryos. *Reproduction* 128: 703–708.
50. Ooi SK, Qiu C, Bernstein E, Li K, Jia D, et al. (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. *Nature* 448: 714–717.
51. Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S (2004) DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. *J Biol Chem* 279: 27816–27823.
52. Kokalj-Vokac N, Zagorac A, Pristovnik M, Bourgeois CA, Dutrillaux B (1998) DNA methylation of the extraembryonic tissues: an in situ study on human metaphase chromosomes. *Chromosome Res* 6: 161–166.
53. Chapman V, Forrester L, Sanford J, Hastie N, Rossant J (1984) Cell lineage-specific undermethylation of mouse repetitive DNA. *Nature* 307: 284–286.
54. Mann MR, Lee SS, Doherty AS, Verona RI, Nolen LD, et al. (2004) Selective loss of imprinting in the placenta following preimplantation development in culture. *Development* 131: 3727–3735.
55. Gardner DK, Schoolcraft WB, Wagley L, Schlenker T, Stevens J, et al. (1998) A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. *Hum Reprod* 13: 3434–3440.
56. Assou S, Anahory T, Pantesco V, Le Carrouer T, Pellestor F, et al. (2006) The human cumulus-oocyte complex gene-expression profile. *Hum Reprod* 21: 1705–1719.
57. Strom S, Inzunza J, Grinnemo KH, Holmberg K, Matilainen E, et al. (2007) Mechanical isolation of the inner cell mass is effective in derivation of new human embryonic stem cell lines. *Hum Reprod* 22: 3051–3058.
58. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, et al. (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. *Nat Genet* 29: 365–371.
59. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci U S A* 95: 14863–14868.
60. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J (2005) BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. *Nucleic Acids Res* 33: W460–464.